Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06268717 · ClinicalTrials.gov registry record · NA
GI Alpha-Gal Study
A NA study of Irritable Bowel Syndrome and Diarrhea, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06268717: Recruiting NA study of Irritable Bowel Syndrome and Diarrhea, sponsored by University of North Carolina, Chapel Hill.
NCT06268717 is a NA study of Irritable Bowel Syndrome and Diarrhea that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants, below the 144-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06268717, a NA study of Irritable Bowel Syndrome and Diarrhea, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.
Primary Outcome
Presence of allergic reaction within 6 hours of the challenge. Reported as dichotomous: food challenge positive (reaction) or food challenge negative (no reaction).
Conditions Studied
Interventions
- OTHER Ground pork containing alpha-gal
- OTHER Pork meat not containing alpha-gal
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2026-06-02 |
| Phase | NA |
What NCT06268717 shows while recruiting
NCT06268717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 144-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (79% lower).
The record links to 5 conditions, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Ground pork containing alpha-gal is the first listed.
NCT06268717 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06268717 about?
NCT06268717 is a clinical study titled "GI Alpha-Gal Study". This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.
What is the current status of trial NCT06268717?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-10-17. Estimated completion is 2026-06-02.
What conditions does trial NCT06268717 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome, Diarrhea, Abdominal Pain, Vomiting, Alpha-Gal Syndrome.
What interventions are being tested in trial NCT06268717?
The interventions under investigation include: Ground pork containing alpha-gal (OTHER), Pork meat not containing alpha-gal (OTHER).
Who is sponsoring clinical trial NCT06268717?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06268717 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06268717's enrollment target sits among peer trials
30 41st of 47 higher than 6 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
-
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
RECRUITING · NA
-
Well-being in IBS: Strengths and Happiness (WISH) 2.0
RECRUITING · NA
-
Mechanisms of Gulf War Illness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI